Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial

  • Amneal Pharmaceuticals Inc AMRX announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations. 
  • Amneal plans to submit a marketing application for IPX-203 with the FDA in mid-2022.
  • The study demonstrated statistically significant improvement in efficacy for IPX-203 compared to immediate-release CD/LD, even when IPX-203 was dosed on average 3 times per day and immediate-release CD/LD was dosed on average 5 times per day. 
  • IPX-203 treatment resulted in 0.53 more hours of "Good On" time than immediate-release CD/LD when comparing change from baseline.
  • The secondary endpoint for change from baseline in "Off" time showed IPX-203 resulted in significantly less "Off" time compared with immediate-release CD/LD (-0.48 hr). 
  • Analysis of the secondary endpoint for Patients' Global Impression of Change (PGI-C) scores showed 29.7% of patients treated with IPX-203 were "much improved" or "very much improved" compared with 18.8% of patients treated with immediate-release CD/LD.
  • Eight subjects reported serious adverse events (SAEs) in the IPX-203 study arm and four (1.6%) subjects in the immediate-release CD/LD arm. 
  • Treatment-emergent adverse events were reported as (108 [42.2%] for IPX-203, 79 [31.6%] for immediate-release CD/LD). 
  • The most common AEs were nausea, dry mouth, urinary tract infection, and fall.
  • Also SeeAmneal Q2 Earnings Tops Estimates; Backs FY21 Guidance.
  • Price Action: AMRX shares are up 11% at $6.16 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsParkinson’s DiseasePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!